Singapore markets close in 3 hours 54 minutes
  • Straits Times Index

    3,291.05
    +7.11 (+0.22%)
     
  • Nikkei

    27,750.11
    +282.88 (+1.03%)
     
  • Hang Seng

    24,689.32
    +561.47 (+2.33%)
     
  • FTSE 100

    7,589.66
    +26.11 (+0.35%)
     
  • BTC-USD

    41,938.64
    +181.91 (+0.44%)
     
  • CMC Crypto 200

    995.75
    +1.01 (+0.10%)
     
  • S&P 500

    4,532.76
    -44.35 (-0.97%)
     
  • Dow

    35,028.65
    -339.82 (-0.96%)
     
  • Nasdaq

    14,340.25
    -166.64 (-1.15%)
     
  • Gold

    1,840.30
    -2.90 (-0.16%)
     
  • Crude Oil

    87.09
    +0.13 (+0.15%)
     
  • 10-Yr Bond

    1.8270
    -0.0380 (-2.04%)
     
  • FTSE Bursa Malaysia

    1,529.29
    -1.04 (-0.07%)
     
  • Jakarta Composite Index

    6,630.82
    +38.84 (+0.59%)
     
  • PSE Index

    7,239.28
    -22.26 (-0.31%)
     

4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout

·4-min read
4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting